Tailoring Obesity Treatment Trial
Key facts
- Who runs it
- Esbjerg Hospital - University Hospital of Southern Denmark
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2/3
- Started
- 1 Apr 2025
- Ended
- 1 Apr 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Pramlintide Acetate 1 MG/ML
- Semaglutide Pen Injector
- Sodium Chloride 0.9% Inj
- Record updated
- 17 April 2026
- Why it stopped
- suspended by the danish medical agency
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- BMI ≧ 30kg/m2
- HbA1c 39-47 mmol/mol (pre-diabetes)
- Male or female
- Aged >18 years of age and <70 years
- Negative pregnancy test, and willing to use contraceptives during the study period
Who cannot take part
- Current or recent (<6 months) treatment with GLP1 RA's
- Previous gastrointestinal surgery that might affect gastric emptying, nutritional absorption and postprandial GI peptide production
- Use of any antipsychotic drugs
- Use of any antiresorptive or bone-anabolic drugs or fractures within < 6 months
- Newly (< 3 months) initiated hormonal contraceptive or other hormone therapy
- Presence of diabetes with or without treatment
- History of acute or chronic pancreatitis
- Chronic kidney disease
- Presence of Binge eating disorder
- Use of systemic oral glucocorticoids within < 6 months
- Recent (<3 months) weight loss ≧ 1% of body weight
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The two main aims of this clinical study is;
Read full original descriptionShow less
1. To investigate if the results from a series of physiological tests and questionnaires prior to treatment, can be used to predict the treatment response to obesity medication 2. To investigate the effect of combining semaglutide and pramlintide on various aspects of appetite, food preference and eating habits.
The study is planed as a 26 week, double blinded, randomized, placebo controlled trial. The goal is to include N=40. They will all receive weekly semaglutide injections. After 24 weeks they will be randomized to receive either an amylin analog (pramlintide) or placebo as a continuous infusion for two weeks, in addition to weekly semaglutide.
The results from this study will contribute to identifying possible predictors of treatment response, enabling optimal individualized medical weight loss treatment. As well as providing knowledge on the complex interplay between incretin hormones and their effects on appetite and eating habits.
The 2 groups in the trial
- Semaglutide and placeboExisting treatment, for comparison
All subjects will receive weekly semaglutide inj. for 26 weeks. After 24 weeks of treatment, this group will be randomized to receive placebo, in addition to semaglutide for the last two weeks of the study.
Treatment: Semaglutide Pen Injector and Sodium Chloride 0.9% Inj
- Semaglutide and pramlintideTreatment being tested
All subjects will receive weekly semaglutide inj. for 26 weeks. After 24 weeks of treatment, this group will be randomized to receive pramlintide, in addition to semaglutide for the last two weeks of the study.
Treatment: Pramlintide Acetate 1 MG/ML and Semaglutide Pen Injector
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- The Impact of Pramlintide on Top of Semaglutide in Obese People With Prediabetes
- Record updated
- 17 April 2026